ArticleNature2013
Tumour heterogeneity in the clinic.
Article in Nature, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 630 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
630 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Comparative Effectiveness and Safety of FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Metastatic Colorectal Cancer: A GRADE-assessed Systematic Review and Meta-analysis.Journal of gastrointestinal cancer · 2026Pooled it
- Modeling metastasis and predicting drug response with malignant effusion-derived organoids: a systematic review and quantitative assessment.Journal of translational medicine · 2026Pooled it
- Liquid biopsy in non-small cell lung cancer: a meta-analysis of state-of-the-art and future perspectives.Frontiers in genetics · 2023Pooled it
- Tissue-Based Markers as a Tool to Assess Response to Neoadjuvant Radiotherapy in Rectal Cancer-Systematic Review.International journal of molecular sciences · 2022Pooled it
- Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trial.BMJ (Clinical research ed.) · 2026Trial
- Comparison of two close-packing methods for vertex placement in lattice radiotherapy (LRT).Journal of applied clinical medical physics · 2026Article
- Tumor-Type-Specific Tumor Mutational Burden Cutoffs for Improved Immune Checkpoint Inhibitor Outcome Prediction: Large-Scale Analysis with Real-World Targeted Next-Generation Sequencing Data.Cancer research and treatment · 2026Article
- Article
- FOXP1 Knockdown Reprograms Th9 CAR-T Cells to Overcome Antigen Escape.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A guide to understanding tumour evolution through the lens of population genetics.Nature reviews. Cancer · 2026Review
- Understanding the Epigenetic Landscape of Barrett's Esophagus and Esophageal Cancer: A Review of Current Findings, Caveats and Future Directions.Genes, chromosomes & cancer · 2026Review
- An interpretable biparametric MRI habitat radiomics model for predicting bone metastasis in prostate cancer: a dual-center study.Translational andrology and urology · 2026Article
- High-spatiotemporal resolution deuterium metabolic imaging enables in vivo phenotyping of intra- and intertumoral heterogeneity.Science advances · 2026Article
- ITHindex: An integrated web-based platform for intratumor heterogeneity evaluation.PLOS digital health · 2026Article
- 3D biomimetic microgel platform for multiple myeloma: Approaching tumor microenvironment on cell lines and patient-derived cells.Materials today. Bio · 2026Article
- Compact Tabletop Magnetic Resonance Elastography for Mapping Soft Tissue Viscoelasticity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Spatial architecture of tertiary lymphoid structures represents an independent prognostic dimension in hepatocellular carcinoma.Journal for immunotherapy of cancer · 2026Article
- Recent advancements and limitations of intestinal organoids for clinical applications.Progress in biomedical engineering (Bristol, England) · 2026Review
- Pre-analytical optimization of cell-free DNA and extracellular vesicle-derived DNA for mutation detection in liquid biopsies.Molecular oncology · 2026Article
- CancerSubtyper: a deep learning framework for cancer subtyping through DNA methylation data.Epigenetics & chromatin · 2026Article
570 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Recent therapeutic advances in oncology have been driven by the identification of tumour genotype variations between patients, called interpatient heterogeneity, that predict the response of patients to targeted treatments. Subpopulations of cancer cells with unique genomes in the same patient may exist across different geographical regions of a tumour or evolve over time, called intratumour heterogeneity. Sequencing technologies can be used to characterize intratumour heterogeneity at diagnosis, monitor clonal dynamics during treatment and identify the emergence of clinical resistance during disease progression. Genetic interpatient and intratumour heterogeneity can pose challenges for the design of clinical trials that use these data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.